Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials

PURPOSE: Abemaciclib in combination with endocrine therapy (ET) has demonstrated significant efficacy benefits in HR+ , HER2− advanced breast cancer patients in the Phase 3 studies MONARCH 2 (fulvestrant as ET) and MONARCH 3 (letrozole or anastrozole as ET). Here, we report age-specific safety and e...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Breast Cancer Res Treat
Auteurs principaux: Goetz, Matthew P., Okera, Meena, Wildiers, Hans, Campone, Mario, Grischke, Eva-Maria, Manso, Luis, André, Valérie A. M., Chouaki, Nadia, San Antonio, Belén, Toi, Masakazu, Sledge, George W.
Format: Artigo
Langue:Inglês
Publié: Springer US 2021
Sujets:
Clinical Trial
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7990838/
https://ncbi.nlm.nih.gov/pubmed/33392835
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-06029-y
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires